Sexual health
PT-141
Bremelanotide, Vyleesi
PT-141 (bremelanotide) is a melanocortin receptor agonist approved by the FDA as Vyleesi for one specific group: premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is often discussed for other groups, which the approval does not cover.
Key facts
- Commonly discussed for: low sexual desire.
- Evidence (B): Two phase 3 RECONNECT trials randomized 1,267 women and showed modest but statistically significant improvements in desire and distress versus placebo, with more nausea, flushing and headache. Approval is limited to premenopausal women with HSDD.
- FDA status: FDA-approved. FDA approved Vyleesi in June 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
- Legitimate access: Rx brand.
- Last reviewed: October 1, 2026.
Thinking about PT-141?
Add it to your stack, then bring the list to a licensed provider. They can tell you whether it fits your health picture and what the legitimate options are. Peptiblox never sells peptides or links to sellers. Check the legal status tracker for the latest FDA changes.
Open my stack →